Last Month(1)
Analyst Downgrades(2)
Analyst Update(2)
Analyst Upgrades(1)
Best and Worst Stocks(1)
Buzz Stocks(2)
By the Numbers(5)
Editor's Pick(1)
Expectational Analysis(2)
Indexes and ETFs(2)
Intraday Option Activity(1)
Opening View(2)
Quantitative Analysis(2)
Stocks On the Move(2)

8/28/2017 12:29 PM
Biotechs are buzzing today on news of Gilead Sciences' $12 billion buyout of cancer specialist Kite Pharma Inc (NASDAQ:KITE). While KITE's 28% surge serving as a tailwind for the sector, drug stocks ...
6/27/2017 1:37 PM
Biotech stocks have been hot lately, with the SPDR S&P Biotech ETF (XBI) flirting with annual highs. What's more, the exchange-traded fund (ETF) is one of the best to own in the month of July, histor...
6/14/2017 9:59 AM
Fed meetings obviously have a major impact on a number of sectors, including bank and housing stocks. One group that isn't usually discussed around Fed time is drug stocks, but that's going to change...
6/14/2017 9:05 AM
Dow Jones Industrial Average (DJIA) futures are trading north of fair value, after the blue-chip index hit a record high on Tuesday. All eyes will be on the Fed today. With a rate hike already pri...
5/23/2017 3:40 PM
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) is trading down 9% at $104.97 -- fresh off a three-year low at $102.47 -- amid a busy session for the stock. Roughly 1.5 million ALXN shares have changed ha...

Welcome to Schaeffer's Investment Research! We are a privately held provider of stock and options trading recommendations, options education, and market commentary, headquartered in Cincinnati, Ohio. Founded in 1981 by industry pioneer Bernie Schaeffer, we've since become a trusted source of research and analysis for individual investors and major financial media outlets alike.

Partner Center